Filibuvir

RNA-directed RNA polymerase (NS5B) inhibitor treatment of hepatitis C virus infection

L. Kapelusznik, E. L. Heil, Zelalem Temesgen, R. Talwani

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Filibuvir is a non-nucleoside inhibitor (NNI) of the hepatitis C virus (HCV) RNA-directed RNA polymerase (NS5B). Specifically, filibuvir works by noncovalently binding to the "thumb 2" pocket of NS5B. Phase I monotherapy studies demonstrated that filibuvir is safe, well tolerated and resulted in a rapid reduction in HCV RNA. Results from a 4-week phase IIa study of three doses of filibuvir given in combination with pegylated interferon (peg-IFN) and ribavirin, followed by 44 weeks of peg-IFN and ribavirin, showed an increased rapid virological response rate (RVR; undetectable HCV RNA after 4 weeks) compared to peg-IFN and ribavirin alone. A trial evaluating 24 weeks of filibuvir in combination with peg-IFN and ribavirin has recently completed enrollment and data from this trial will be forthcoming.

Original languageEnglish (US)
Pages (from-to)767-775
Number of pages9
JournalDrugs of the Future
Volume37
Issue number11
DOIs
StatePublished - 2012

Fingerprint

RNA Replicase
Virus Diseases
Hepacivirus
Ribavirin
Interferons
RNA
Thumb
PF 00868554

Keywords

  • Filibuvir
  • Hepatitis C virus
  • PF-868554
  • RNA-directed RNA polymerase inhibitor

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Filibuvir : RNA-directed RNA polymerase (NS5B) inhibitor treatment of hepatitis C virus infection. / Kapelusznik, L.; Heil, E. L.; Temesgen, Zelalem; Talwani, R.

In: Drugs of the Future, Vol. 37, No. 11, 2012, p. 767-775.

Research output: Contribution to journalArticle

@article{d90dc592a3944a8195de8c7046044dcf,
title = "Filibuvir: RNA-directed RNA polymerase (NS5B) inhibitor treatment of hepatitis C virus infection",
abstract = "Filibuvir is a non-nucleoside inhibitor (NNI) of the hepatitis C virus (HCV) RNA-directed RNA polymerase (NS5B). Specifically, filibuvir works by noncovalently binding to the {"}thumb 2{"} pocket of NS5B. Phase I monotherapy studies demonstrated that filibuvir is safe, well tolerated and resulted in a rapid reduction in HCV RNA. Results from a 4-week phase IIa study of three doses of filibuvir given in combination with pegylated interferon (peg-IFN) and ribavirin, followed by 44 weeks of peg-IFN and ribavirin, showed an increased rapid virological response rate (RVR; undetectable HCV RNA after 4 weeks) compared to peg-IFN and ribavirin alone. A trial evaluating 24 weeks of filibuvir in combination with peg-IFN and ribavirin has recently completed enrollment and data from this trial will be forthcoming.",
keywords = "Filibuvir, Hepatitis C virus, PF-868554, RNA-directed RNA polymerase inhibitor",
author = "L. Kapelusznik and Heil, {E. L.} and Zelalem Temesgen and R. Talwani",
year = "2012",
doi = "10.1358/dof.2012.037.011.1875980",
language = "English (US)",
volume = "37",
pages = "767--775",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "11",

}

TY - JOUR

T1 - Filibuvir

T2 - RNA-directed RNA polymerase (NS5B) inhibitor treatment of hepatitis C virus infection

AU - Kapelusznik, L.

AU - Heil, E. L.

AU - Temesgen, Zelalem

AU - Talwani, R.

PY - 2012

Y1 - 2012

N2 - Filibuvir is a non-nucleoside inhibitor (NNI) of the hepatitis C virus (HCV) RNA-directed RNA polymerase (NS5B). Specifically, filibuvir works by noncovalently binding to the "thumb 2" pocket of NS5B. Phase I monotherapy studies demonstrated that filibuvir is safe, well tolerated and resulted in a rapid reduction in HCV RNA. Results from a 4-week phase IIa study of three doses of filibuvir given in combination with pegylated interferon (peg-IFN) and ribavirin, followed by 44 weeks of peg-IFN and ribavirin, showed an increased rapid virological response rate (RVR; undetectable HCV RNA after 4 weeks) compared to peg-IFN and ribavirin alone. A trial evaluating 24 weeks of filibuvir in combination with peg-IFN and ribavirin has recently completed enrollment and data from this trial will be forthcoming.

AB - Filibuvir is a non-nucleoside inhibitor (NNI) of the hepatitis C virus (HCV) RNA-directed RNA polymerase (NS5B). Specifically, filibuvir works by noncovalently binding to the "thumb 2" pocket of NS5B. Phase I monotherapy studies demonstrated that filibuvir is safe, well tolerated and resulted in a rapid reduction in HCV RNA. Results from a 4-week phase IIa study of three doses of filibuvir given in combination with pegylated interferon (peg-IFN) and ribavirin, followed by 44 weeks of peg-IFN and ribavirin, showed an increased rapid virological response rate (RVR; undetectable HCV RNA after 4 weeks) compared to peg-IFN and ribavirin alone. A trial evaluating 24 weeks of filibuvir in combination with peg-IFN and ribavirin has recently completed enrollment and data from this trial will be forthcoming.

KW - Filibuvir

KW - Hepatitis C virus

KW - PF-868554

KW - RNA-directed RNA polymerase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84952986521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952986521&partnerID=8YFLogxK

U2 - 10.1358/dof.2012.037.011.1875980

DO - 10.1358/dof.2012.037.011.1875980

M3 - Article

VL - 37

SP - 767

EP - 775

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 11

ER -